Grifols Invests in Alkahest to Develop Plasma-Based Products
Grifols has made a major equity investment in Alkahest to work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system.
Saving the Aging Brain: Grifols Attacks Alzheimer’s Disease Head-On
Grifols, the world’s third largest manufacturer of plasma-based therapeutics and a leader in immunohematology and transfusion medicine diagnostics, has been patiently developing a novel approach to treatment of AD, based on plasma exchange and replacement with donor human albumin.
In the Pipeline: Novel Plasma Proteins for Major Cardiovascular Disorders
OVER THE 70 years since biochemist Edwin Cohn and his Harvard Medical School laboratory first purified human albumin for use in severe burns and hemorrhagic trauma, nearly 30 therapeutic proteins from human plasma have been purified, proven safe and effective and approved for use. Most of these products (Table 1) are indicated as replacement therapies […]
Thirty Years On, IVIG Clinical Research Keeps Rolling
Thirty years after its quiet introduction, unabated global research interest in IVIG reflects just how much remains unknown about its therapeutic potential.
The Plasma Industry: Investing Today to Ensure IG and Albumin Supply for Tomorrow
The plasma industry continues to plan and invest for the future to assure that immunoglobulin, albumin and other life-critical plasma products are on the shelf when they’re needed.
IVIG as Effective as Plasma Exchange in Treating Guillain Barré Syndrome
A meta-analysis showed IVIG was as effective as plasma exchange in reducing Guillain Barré syndrome disability scores, with no significant difference in adverse events.
Human Plasma Products: Two Decades of Unsurpassed Safety
With the combination of proven, robust preemptive pathogen reduction and constant vigilance by industry and drug regulators, plasma products can be prescribed with more confidence than ever.
Plasma Exchange: New Uses for a Therapeutic Workhorse
THE IDEA OF removing harmful substances in the blood by apheresis — from the Greek aphairesis meaning “taking away” — originated nearly a century ago in Baltimore. In 1914, Dr. John Abel and his team at Johns Hopkins Medical School repeatedly removed quantities of blood from dogs, discarded the liquid plasma portion and reinfused the […]
Plasma Therapies: Where Are We Now?
Several key variables play a role in the promising possibilities for lifesaving plasma protein therapies.
Plasma Therapies: IG in the Driver’s Seat
As plasma protein therapies evolve to satisfy the world’s demand, the volume and costs of the therapies produced is dictated by which of the therapies is in highest demand.